Voyager Therapeutics

VYGR

Market cap $252M

Overview Fund Trends Analyst Outlook Journalist POV

4.55 USD

--0.22

4.61%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

4.50

--0.05

1.1%

1 day

-4.61%

5 days

-12.67%

1 month

10.98%

3 months

38.72%

6 months

30.37%

Year to date

-23.79%

1 year

-29.24%

5 years

-58.75%

10 years

-74.37%

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 172

Healthcare Biotechnology